Skip to main content
. Author manuscript; available in PMC: 2010 Feb 1.
Published in final edited form as: Int J Cancer. 2009 Feb 1;124(3):614–621. doi: 10.1002/ijc.24012

Figure 1.

Figure 1

Median titers, inter-quartile ranges, and maximum observed titers of (A) anti-EBNA1, (B) anti-EBNA2, and (C) anti-VCA and prevalence of (D) anti-EA seropositivity and (E) low EBNA1:EBNA2 ratio, in HTLV-I-uninfected (□) and HTLV-I-infected (■) participants from Japan and Jamaica.